Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Investigating the Differences in Binding of Grb10 to GIGYF1 and GIGYF2 in humans and mice using Co-immunoprecipitation and a Bioinformatical Approach
EF 2023-24
Résumé
The dysfunction of insulin receptors has been linked to various diseases such as Familial Parkinson’s Disease, decreased cognitive function from diabetes and autism. Although proteins such as Grb10 which have an important role in regulating how active the insulin receptors are, when mutations arise in Grb10, it overreacts by decreasing the activity of the insulin receptors through its inhibition. This leads to the diseases and disease states mentioned earlier. The importance of being able to prevent insulin from entering into a cell is extremely important and as such the inhibition of the receptors is a function that Grb10 has when it binds to either a protein known as GIGYF1, or a protein known as GIGYF2. This binding occurs due to two corresponding pockets on Grb10 and GIGYF1 or GIGYF2 that are able to interact with each other, causing the two proteins to bind to each other. This pocket on Grb10 is called the PPGF motif and it has been shown previously that when the pocket is removed, Grb10 is no longer able to bind to GIGYF1 or GIGYF2. The problem that this research is aiming to tackle is the fact that this binding capability of Grb10 has only been proven in mouse cells with the mouse version of Grb10 and GIGYF1 or GIGYF2. This has never been shown to occur in human cells with the human versions of the proteins. Additionally, the PPGF motif does not exist in the human version of Grb10 and as such it is suggested that Grb10 does not bind to GIGYF1 or GIGYF2 or at least to the complementary pockets in both proteins. Proving whether or not binding in the human versions occurs is an important first step in better understanding the role that Grb10 plays in inhibition of insulin receptors and the associated diseases to that inhibition.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506171
Name
Shpilman Israel
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Differences in Binding of Grb10 to GIGYF1 and GIGYF2 in humans and mice using Co-immunoprecipitation and a Bioinformatical Approach
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autism Spectrum Disorder; Co-Immunoprecipitation; Diabetes-Induced Cognitive-Impairment; Exogenous Expression; Familial Parkinson Disease; Gigyf1; Gigyf2; Grb10; Neurodegeneration; Protein Binding
Abstract
The dysfunction of insulin receptors has been linked to various diseases such as Familial Parkinson’s Disease, decreased cognitive function from diabetes and autism. Although proteins such as Grb10 which have an important role in regulating how active the insulin receptors are, when mutations arise in Grb10, it overreacts by decreasing the activity of the insulin receptors through its inhibition. This leads to the diseases and disease states mentioned earlier. The importance of being able to prevent insulin from entering into a cell is extremely important and as such the inhibition of the receptors is a function that Grb10 has when it binds to either a protein known as GIGYF1, or a protein known as GIGYF2. This binding occurs due to two corresponding pockets on Grb10 and GIGYF1 or GIGYF2 that are able to interact with each other, causing the two proteins to bind to each other. This pocket on Grb10 is called the PPGF motif and it has been shown previously that when the pocket is removed, Grb10 is no longer able to bind to GIGYF1 or GIGYF2. The problem that this research is aiming to tackle is the fact that this binding capability of Grb10 has only been proven in mouse cells with the mouse version of Grb10 and GIGYF1 or GIGYF2. This has never been shown to occur in human cells with the human versions of the proteins. Additionally, the PPGF motif does not exist in the human version of Grb10 and as such it is suggested that Grb10 does not bind to GIGYF1 or GIGYF2 or at least to the complementary pockets in both proteins. Proving whether or not binding in the human versions occurs is an important first step in better understanding the role that Grb10 plays in inhibition of insulin receptors and the associated diseases to that inhibition.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shpilman, Israel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~